Sugi Predict

Sugi Predict / Compounds / SCHEMBL166467

SCHEMBL166467

SCHEMBL166467

COC(=O)c1cscc1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.52
▸ HSD17B10 Q99714 3/20 0.52
▸ CFTR P13569 3/20 0.52
▸ KDM4E B2RXH2 7/20 0.48
▸ GAA P10253 6/20 0.47
▸ MAPT P10636 3/20 0.47
▸ HPGD P15428 3/20 0.47
▸ GLA P06280 2/20 0.47
▸ ATM Q13315 2/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ CASP7 P55210 1/20 0.47
▸ ABL1 P00519 1/20 0.46
▸ TSHR P16473 3/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ POLB P06746 2/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1845722 0.98 ALDH1A1 (0.50) ALDH1A1HSD17B10CFTRKDM4EGAA
SCHEMBL68934 0.84 TSHR (0.46) ALDH1A1HSD17B10CFTRKDM4EGAA
SCHEMBL4184254 0.79 ALDH1A1 (0.56) ALDH1A1HSD17B10KDM4EGAAMAPT
Hydrochloric Acid SCHEMBL1492019 0.77 ALDH1A1 (0.54) ALDH1A1HSD17B10KDM4EGAAMAPT
SCHEMBL8197514 0.77 LMNA (0.50) ALDH1A1HSD17B10CFTRKDM4EGAA
SCHEMBL2619615 0.77 CYP2A6 (0.45) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL13913259 0.77 PTPN1 (0.46) ALDH1A1HSD17B10CFTRKDM4EGAA
SCHEMBL17918611 0.75 TSHR (0.39) ALDH1A1HSD17B10CFTRKDM4EGAA
SCHEMBL18047964 0.75 GSK3B (0.52) ALDH1A1HSD17B10CFTRKDM4EGAA
SCHEMBL16289854 0.75 TSHR (0.39) ALDH1A1HSD17B10CFTRKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118240212-A Material for forming polyimide by electrophoresis, insulating material and electrophoresis coating method 比亚迪股份有限公司 2024-06-25 — — CN claimed
EP-3901151-B1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2026-04-01 — — EP disclosed
US-20250296928-A1 A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF IOMX THERAPEUTICS AG (DE) 2025-09-25 — — US disclosed
EP-3617213-B1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARMACEUTICAL CO LTD (KR) 2025-02-19 — — EP disclosed
CN-118440063-A QC and BACE1 multi-targeting inhibitor and preparation method and application thereof 深圳大学 2024-08-06 — — CN disclosed
CN-118369321-A Synthetic schemes and procedures for preparing SIK3 inhibitors and intermediates thereof 艾奥麦克斯治疗公司 2024-07-19 — — CN disclosed
WO-2024131937-A1 COMPOUND SERVING AS EIF4E INHIBITOR AND USE THEREOF 南京圣和药业股份有限公司 2024-06-27 — — WO disclosed
CN-118240212-A Material for forming polyimide by electrophoresis, insulating material and electrophoresis coating method 比亚迪股份有限公司 2024-06-25 — — CN disclosed
CN-118239963-A Compounds as eIF4E inhibitors and uses thereof 南京圣和药业股份有限公司 2024-06-25 — — CN disclosed
WO-2024103067-A1 COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF RIBOMETRIX, INC. (US) 2024-05-16 — — WO disclosed
WO-1998016520-A1 THE PREPARATION AND USE OF ORTHO-SULFONAMIDO HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1998-04-23 — — WO disclosed
EP-0331919-B1 PROCESS FOR THE PREPARATION OF THIOPHENE DERIVATIVES AND DIHYDROTHIOPHEN-1-OXIDES HOECHST AKTIENGESELLSCHAFT (DE) 1993-08-04 — — EP disclosed
US-5166346-A Plant safening agents and drugs HOECHST AKTIENGESELLSCHAFT (DE) 1992-11-24 — — US disclosed
EP-0298542-B1 PROCESS FOR PREPARING THIOPHENE DERIVATIVES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1990-12-12 — — EP disclosed
US-4939137-A Ring-fused thienopyrimidinedione derivatives ORTHO PHARMACEUTICAL CORPORATION (US) 1990-07-03 — — US disclosed
EP-0331919-A2 Process for the preparation of Thiophene derivatives and dihydrothiophen-1-oxides HOECHST AKTIENGESELLSCHAFT (DE) 1989-09-13 — — EP disclosed
US-4847386-A AMINATION, DEHYDRATION SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1989-07-11 — — US disclosed
US-4835157-A Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents ORTHO PHARMACEUTICAL CORPORATION (US) 1989-05-30 — — US disclosed
EP-0298542-A1 Process for preparing thiophene derivatives SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1989-01-11 — — EP disclosed
EP-0126970-A2 Anxiolytic and anti-depressant thienopyridine derivatives BEECHAM GROUP PLC (GB) 1984-12-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296928-A1 A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF SIK3, SIK1, SIK2 ALDH1A1 4067/4885HSD17B10 1741/4885CFTR 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.